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of error terms in the utility function in several ways. The survey questionnaire includes 
four attributes associated with lung cancer in Korea (incidence rates, survival rates, 
treatment costs, and monthly insurance premium), socio-economic status, antecedent 
variables, and questions regarding risk averseness and subjective health evaluation. 
RESULTS: The estimates of MWTP between survival rate and monthly insurance 
premium and MTWP between total treatment costs for lung cancer and monthly 
insurance premium, by employing “Hybrid Conditional Fixed Effects Logit Model” 
to ﬁgure out the existence of heterogeneity of any observed and unobserved compo-
nents, are reﬂecting ranges of 261 KRW∼286 KRW and 3414 KRW∼4538 KRW, 
respectively. CONCLUSIONS: Compared to female counterparts, male respondents 
have higher MWTP of monthly insurance premium for two related attributes. Besides, 
married and younger respondents, with higher income and education have more 
MWTP compared to their respective counterparts. One interesting point is that depen-
dents’ MWTP of survival rate is higher than that of insurance premium payers 
although MTWP of total treatment costs for dependents is signiﬁcantly lower than 
premium payers’ MWTP.
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OBJECTIVES: This study, using DCE method, ﬁgures out the characteristics of the 
decision-making for liver cancer treatment and investigates the attributes affecting the 
respondents’ choice. Also it ascertains marginal willingness to pay and relative prefer-
ences for liver cancer treatment among the general population of 600 respondents in 
Korea. METHODS: In the survey, the respondents are asked to choose more than one 
discrete choice option, resulting in multiple observations for each individual. For each 
pair-wise comparison of choice set, the respondent will make a choice among three 
alternatives; A, B, or opt out. Thus, the nested-logit model using full maximum likeli-
hood allows us to empirically estimate multi-levels of dependent variables. For the 
robustness check of our empirical results, we try considering the nature of distribution 
of error terms in the utility function in several ways. The survey questionnaire includes 
four attributes associated with liver cancer in Korea (incidence rates, survival rates, 
treatment costs, and monthly insurance premium), socio-economic status, antecedent 
variables, and questions regarding risk averseness and subjective health evaluation. 
RESULTS: The estimates of MWTP between survival rate and monthly insurance 
premium and MTWP between total treatment costs for liver cancer and monthly 
insurance premium, by employing “Hybrid Conditional Fixed Effects Logit Model” 
to ﬁgure out the existence of heterogeneity of any observed and unobserved compo-
nents, are reﬂecting ranges of 212 KRW∼294 KRW and 3458 KRW∼4777 KRW, 
respectively. CONCLUSIONS: Compared to female counterparts, male respondents 
have higher MWTP of monthly insurance premium for two related attributes. Besides, 
married respondents, with higher education have more MWTP compared to their 
respective counterparts. One interesting point is that MWTP of high income group is 
lower than that of low income counterparts. This might be related to a lower alcohol 
consumption of high incomers who are less prone to liver cancer compared to low 
incomers.
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OBJECTIVES: Human Papilloma Virus (HPV) is a sexually transmitted disease (STD) 
and is the leading cause of cervical cancer. Merck’s Gardasil, an HPV vaccine in the 
US, protects against cervical cancer and genital warts. The CDC recommends HPV 
vaccination for females 11–12 years old, yet vaccination rates vary signiﬁcantly by 
state from 15.8% to 54.7%. The objective of this study was to evaluate coverage of 
HPV vaccination and explore explanation for variation across the United States. 
METHODS: Our study included analysis of CDC vaccination rates, American Com-
munity Survey (Census) data, and additional government agency datasets. The vac-
cination rate is deﬁned as vaccination of the 1st dose (three doses are recommended 
in total). Health care system and socioeconomic characteristics were identiﬁed and 
evaluated with respect to HPV vaccine coverage. Regression models were run on each 
state-level variable separately. RESULTS: The correlation between HPV vaccine rates 
and the percent of children attending religious service on a weekly basis resulted in a 
signiﬁcant inverse relationship. The analysis yielded a R2 value of 0.41, an f-value of 
33.47 and a −5.79 t Stat score. Teen birth rates also resulted in a negative correlation 
with a R2 value of 0.18, an f-value of 10.78 and a −3.28 t Stat score. Pediatricians 
per 1000 state inhabitants and percent of people who completed a bachelor’s degree 
yielded positive correlation to vaccination rates with R2 values of 0.18 and 0.16, 
respectively. Factors that did not correlate to vaccination rates included cervical cancer 
rates, STD rates, abortion rates, and high school graduation rates. CONCLUSIONS: 
An array of socio-economic and health care system variables were correlated with the 
HPV vaccination rates by state. Public health programs focused on inﬂuencing these 
state-level variables may precipitate improvement in HPV coverage.
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OBJECTIVES: To determine prevalence and correlates of Human Papillomavirus 
(HPV) vaccination in adolescent girls who were recommended to receive vaccine by 
their health care providers. METHODS: A retrospective cross-sectional analysis 
involving adolescent girls (11–17 years) was conducted using the 2007 National 
Survey of Children’s Health (NSCH). The analysis focused on adolescent girls who 
were recommended to receive HPV vaccine. Descriptive weighted statistics was used 
to examine prevalence of HPV vaccination. Multivariate logistic regression within 
the conceptual framework of Andersen Behavioral Model was used to examine the 
correlates of HPV vaccination in this at-risk population. RESULTS: Of 14.43 million 
adolescent girls in the United States, 3.69 million or 25.54 % (95% Conﬁdence 
Interval [CI], 24.02–27.06) were recommended to receive the HPV vaccine by their 
health care provider. Amongst those who were recommended, only 48.75% (95% 
CI, 45.37–52.13) received the HPV vaccine. The majority who received the HPV 
vaccine were in the 13–17 age groups (82.67%), white (66.94%), and non-Hispanic 
(84.83%). Multivariate logistic regression revealed that enabling (socioeconomic 
status) and predisposing (number of adults in the household and preventive medical 
care visit) factors were signiﬁcantly associated with the HPV vaccination. Children 
living at 100–200% of the Federal Poverty Level (FPL) (Odds Ratio [OR] 0.54, 
95% CI 0.30–0.98) were less likely to receive the vaccine than those living below 
100% of the FPL. Children in households with two or more adults (OR 0.51, 95% 
CI, 0.33–0.80) were negatively associated and those with any previous preventive 
medical care visit (OR 2.28, 95% CI, 1.36–3.84) were positively associated with 
HPV vaccination. CONCLUSIONS: Less than half of the girls received HPV vaccine 
among those who were recommended by their health care provider. The study ﬁnding 
emphasizes importance of predisposing and enabling factors for HPV vaccination. 
Policy and educational efforts can focus on these factors to improve HPV vaccination 
rates.
PCN124
IDEAL VIAL SIZE FOR BORTEZOMIB: REAL WORLD DATA ON WASTE 
AND COST REDUCTION IN MULTIPLE MYELOMA (MM)
Castro APC, Alves AFF, Clark LGO, Santos FS, Clark O, Engel T, Pegoretti B
Evidencias, Campinas, Brazil
OBJECTIVES: Single size vials of chemotherapy drugs may be a source of waste and 
increase in treatment costs. Bortezomib, a drug frequently used in MM treatments, is 
available in a 3.5mg vial (above the average dose commonly prescribed) without 
antimicrobial preservatives, making mandatory its administration within 8 hours of 
preparation. Through real world data collected from Evidencias® a dedicated data-
base of cancer treatments (www.evidencias.com.br) we aimed to demonstrate which 
would be the optimal vial presentation for Bortezomib. METHODS: From November 
2007 to October 2009 all patients with MM treated with Bortezomib were identiﬁed 
on Evidencias®. Analysis of prescribed, dispensed and wasted doses, their costs and 
which would be the ideal vial size were performed. RESULTS: We identiﬁed 35 
patients that received Bortezomib in this period (mean body surface area of 1.73 m2). 
Mean prescribed dose per infusion was 2.1 mg which generated a waste of 1.4 mg 
(40%) of each vial. Due to this waste, the total amount of the drug used was 1 
907.6 mg at a cost of US$1 192,849.98 to cover the prescribed amount of 1,216.14 mg 
(US$727,923.08). The total waste was of 691.36 mg (US$464,926.89). The patients 
received a total of 131 cycles (mean of 3.77). The mean waste was 4.89 mg per cycle 
and 14.4 mg per patient. If a 3 mg vial were available, (maintaining a proportional 
price to the 3.5 mg one) the total cost of treatment would be US$994,836.88 (16.6% 
lower) and the drug waste would be reduced by 34.72% (9.4 mg per patient). CON-
CLUSIONS: A simple adjustment in vial size reduces Bortezomib waste by 34.72% 
and results in a cost reduction of 16.6%. Further models using different vial sizes, 
combined to dose adjustment and patient scheduling may increase the economy even 
more.
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OBJECTIVES: Docetaxel (D) is well recognized as the ﬁrst-line chemotherapy in 
patients with metastatic prostate cancer (PC). Of interest is the relationship between 
the number of treatment cycles and overall survival (OS) beneﬁt. This study investi-
gated the relationship between number of cycles and OS in a community practice. 
METHODS: The Georgia Cancer Specialist Database (2003–2008) was used. Patients 
with initial stage IV PC receiving D were followed from the date of ﬁrst D use to the 
earlier of death or loss to follow-up. The three-month period prior to the ﬁrst D use 
was the baseline. Patients were stratiﬁed into <10 vs. ≥10 groups based on mean cycle 
number. OS was compared using the Kaplan-Meier curve. The impact of cycle number 
on OS was further examined using multivariate Cox model with adjustment of age, 
comorbidity, baseline PSA, baseline bisphosphonate use, hormonal therapies and other 
